uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Circulating tumor cell counts is a better predictor of overall survival than dynamic tumor size changes – a quantitative modeling framework
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaceutisk biovetenskap. Uppsala University. (Pharmacometrics)ORCID-id: 0000-0003-4677-4741
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaceutisk biovetenskap. (Pharmacometrics)
Department of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Vise andre og tillknytning
(engelsk)Inngår i: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265Artikkel i tidsskrift (Annet vitenskapelig) Submitted
Abstract [en]

Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We here present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS.

Experimental design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase 3 study (CAIRO2).

Results: A tumor size model of tumor quiescence and drug-resistance, was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). A CTC count≥3/7.5 mL (hazard ratio=3.51, 95% confidence interval: 2.85-4.32), as described by the CTC model, was a better predictor of OS than tumor size changes. The modeling framework was applied to explore if dose-modifications (increased and reduced) would result in a CTC count below 3/7.5 mL after 1-2 weeks of treatment.

Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size had a strong connection to CTC, its link to OS was weaker. 

HSV kategori
Forskningsprogram
Farmakokinetik och läkemedelsterapi
Identifikatorer
URN: urn:nbn:se:uu:diva-390191OAI: oai:DiVA.org:uu-390191DiVA, id: diva2:1341480
Forskningsfinansiär
Swedish Cancer Society, CAN 2017/626Tilgjengelig fra: 2019-08-08 Laget: 2019-08-08 Sist oppdatert: 2019-08-09
Inngår i avhandling
1. Pharmacometric Evaluation of Biomarkers to Improve Treatment in Oncology
Åpne denne publikasjonen i ny fane eller vindu >>Pharmacometric Evaluation of Biomarkers to Improve Treatment in Oncology
2019 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Cancer is a family of many different diseases with substantial heterogeneity also within the same cancer type. In the era of personalized medicine, it is desirable to identify an early response to treatment (i.e., a biomarker) that can predict the long-term outcome with respect to both safety and efficacy. It is however not uncommon to categorize continuous data, e.g., using tumor size data to classify patients as responders or non-responders, resulting in loss of valuable information. Pharmacometric modeling offers a way of analyzing longitudinal time-courses of different variables (e.g., biomarker and tumor size), and therefore minimizing information loss.

Neutropenia is the most common dose-limiting toxicity for chemotherapeutic drugs and manifests by a low absolute neutrophil count (ANC). This thesis explored the potential of using model-based predictions together with frequent monitoring of the ANC to identify patients at risk of severe neutropenia and potential dose delay. Neutropenia may develop into febrile neutropenia (FN), a potentially life-threatening condition. Interleukin 6, an immune-related biomarker, was identified as an on-treatment predictor of FN in breast cancer patients treated with adjuvant chemotherapy. C-reactive protein, another immune-related biomarker, rather demonstrated confirmatory value to support FN diagnosis.

Cancer immunotherapy is the most recent advance in anticancer treatment, with immune checkpoint inhibitors, e.g., atezolizumab, leading the breakthrough. In a pharmacometric modeling framework, the area under the curve of atezolizumab was related to tumor size changes in non-small cell lung cancer patients treated with atezolizumab. The relative change from baseline of Interleukin 18 at 21 days after start of treatment added predictive value on top of the drug effect. The tumor size time-course predicted overall survival (OS) in the same population.

Circulating tumor cells (CTCs) are tumor cells that have shed from a tumor and circulate in the blood. CTCs may cause distant metastases, which is related to a poor prognosis. A novel modeling framework was developed in which the relationship between tumor size and CTC count was quantified in patients with metastatic colorectal cancer treated with chemotherapy and targeted therapy. It was also demonstrated that the CTC count was a superior predictor of OS in comparison to tumor size changes.

In summary, IL-6 predicted FN, IL-18 predicted tumor size changes and tumor size changes and CTC counts predicted OS. The results in this thesis were obtained by using pharmacometrics to evaluate biomarkers to improve treatment in oncology.

sted, utgiver, år, opplag, sider
Uppsala: Acta Universitatis Upsaliensis, 2019. s. 85
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 275
Emneord
Pharmacometrics, Biomarkers, Oncology, Population PKPD Modeling, NONMEM
HSV kategori
Forskningsprogram
Farmaceutisk vetenskap
Identifikatorer
urn:nbn:se:uu:diva-390192 (URN)978-91-513-0709-1 (ISBN)
Disputas
2019-09-27, Room B21, Biomedicinskt centrum (BMC), Husargatan 3, Uppsala, 09:15 (engelsk)
Opponent
Veileder
Tilgjengelig fra: 2019-09-05 Laget: 2019-08-09 Sist oppdatert: 2019-09-17

Open Access i DiVA

Fulltekst mangler i DiVA

Søk i DiVA

Av forfatter/redaktør
Netterberg, Ida
Av organisasjonen
I samme tidsskrift
Clinical Cancer Research

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 121 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf